Shares of Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) have received an average broker rating score of 1.00 (Strong Buy) from the one brokers that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a strong buy recommendation.

Analysts have set a 1 year consensus price objective of $10.00 for the company and are anticipating that the company will post ($0.69) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Diffusion Pharmaceuticals an industry rank of 72 out of 256 based on the ratings given to its competitors.

DFFN has been the subject of several recent research reports. ValuEngine downgraded Diffusion Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, February 2nd. HC Wainwright upped their price target on Diffusion Pharmaceuticals to $10.00 and gave the stock a “buy” rating in a report on Wednesday, March 20th.

A hedge fund recently raised its stake in Diffusion Pharmaceuticals stock. Renaissance Technologies LLC increased its stake in shares of Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) by 108.5% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 108,070 shares of the company’s stock after buying an additional 56,230 shares during the quarter. Renaissance Technologies LLC owned 3.20% of Diffusion Pharmaceuticals worth $401,000 at the end of the most recent quarter. 7.72% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NASDAQ:DFFN traded down $1.11 during trading on Friday, reaching $3.66. 469,121 shares of the stock were exchanged, compared to its average volume of 309,633. The company has a quick ratio of 5.35, a current ratio of 5.35 and a debt-to-equity ratio of 0.02. Diffusion Pharmaceuticals has a 1-year low of $1.83 and a 1-year high of $11.00. The firm has a market capitalization of $16.36 million, a price-to-earnings ratio of -0.60 and a beta of 0.21.

Diffusion Pharmaceuticals (NASDAQ:DFFN) last issued its earnings results on Thursday, May 9th. The company reported ($0.81) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.09. Equities research analysts anticipate that Diffusion Pharmaceuticals will post -2.27 earnings per share for the current fiscal year.

About Diffusion Pharmaceuticals

Diffusion Pharmaceuticals Inc, a clinical stage biotechnology company, develops treatments for life-threatening medical conditions. Its lead product candidate is transcrocetinate sodium, which is in Phase III trials for the treatment of glioblastoma multiforme (GBM); Phase II clinical trials for the treatment of pancreatic cancer and metastatic brain cancer; and Phase II trial for the treatment of acute stroke.

Read More: What is a Fiduciary?

Get a free copy of the Zacks research report on Diffusion Pharmaceuticals (DFFN)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Diffusion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diffusion Pharmaceuticals and related companies with's FREE daily email newsletter.